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Aim To explore the relationship between alteration in the 
expression of TWIST, highly conserved transcription fac-
tor from the basic helix-loop-helix family, and apoptosis 
of Hep-2 cells induced by chemotherapeutic agent pacli-
taxel.
Methods Morphological changes of Hep-2 cells were ob-
served by acridine orange cytochemistry staining. Viability 
of Hep-2 cells treated with various concentrations of pa-
clitaxel was examined by cell proliferation assay. Apoptosis 
was examined by flow cytometry. The mRNA and protein 
expression of TWIST in response to paclitaxel at 24 hours, 
48 hours, and 72 hours was examined by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) and Western blot-
ting, respectively.
Results Typical morphological changes of apoptotic cells 
at 24 hours, 48 hours, or 72 hours after treatment wiyth 
paclitaxel (10 × 10−9 mol/L) were observed. The cell survival 
rates significantly decreased in a concentration- and time-
dependent manner (P = 0.001). Paclitaxel-induced apopto-
sis increased with culture time (22.6 ± 5.3% after 24 hours, 
38.7 ± 7.9% after 48 hours, and 52.4 ± 14.3% after 72 hours; 
P = 0.002). Both mRNA and protein expression of TWIST 
was markedly decreased at both mRNA levels and protein 
levels, at 24 hours, 48 hours, and 72 hours in the paclitaxel-
induced apoptosis of Hep-2 cells (P < 0.001).
Conclusion TWIST, which has a significantly decreased ex-
pression in response to paclitaxel in Hep-2 cells, may play a 
pivotal role in paclitaxel-induced apoptosis of Hep-2 cells.
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Laryngeal carcinoma is one of the most aggressive human 
malignancies, which causes substantial annual morbidity 
and mortality (1,2). Over the two past decades, the survival 
rate of the patients has not considerably improved, despite 
multimodal therapeutic strategies, especially chemothera-
py (3,4). Of the chemotherapeutic agents, paclitaxel (Tax-
ol), a natural product derived from the bark of Pacific Yew, 
has been clinically used alone or in combination with oth-
er drugs to treat human cancers. It has been shown that 
paclitaxel exerts effective inhibitory effect on certain types 
of human malignant tumors, including the carcinomas of 
the breast, ovary, lung, esophagus, and head and neck (5-
7). Although in vitro studies have shown that paclitaxel-in-
duced cell death occurs via the apoptotic pathway in sev-
eral tumor cell lines (8), few studies have been conducted 
to examine how paclitaxel exerts its inhibitory effects on 
Hep-2 cells, the human laryngeal carcinoma cell line. Re-
cently, Li et al (9) found that paclitaxel induced apoptosis in 
Hep-2 cell, which was related to the disturbance of cell cy-
cle. However, the precise mechanism by which paclitaxel 
elicits apoptosis in Hep-2 cells is still unclear.
TWIST, which belongs to basic helix-loop-helix family, is a 
highly conserved transcription factor. Previous research has 
confirmed that overexpression of TWIST is found in sever-
al kinds of human cancers (10), which not only promotes 
the immigration and invasion of cancers cells, but also de-
creases the sensitivity to chemotherapy (11,12). Overex-
pression of TWIST may a key for tumor metastasis and drug 
resistance, but the precise mechanism is still unclear (11). 
As yet, there are no studies on the role of TWIST in paclit-
axel-exerted effect on Hep-2 cells. The present study was 
designed to investigate the possible role of TWIST activity 
in paclitaxel-induced apoptosis in Hep-2 cells.
materiaLS and metHodS
Cell culture
The human laryngeal carcinoma cell line Hep-2 was ob-
tained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). The Dulbecco’s modified Eagle’s me-
dium (DMEM) and serum was purchased from GIBCO 
(Carlsbad, CA, USA). TWIST antibody was purchased from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Taxol 
was obtained from Bristol-Myers Squibb Company (New 
York, NY, USA). All other agents were purchased from Sig-
ma (St. Louis, MO, USA). Hep-2 cells were cultured in DMEM 
containing 10% fetal calf serum, 100 U/mL penicillin, and 
100 mg streptomycin at 37°C in a humidified atmosphere 
composed of 95% air and 5% CO2. Cells were regularly sub-
cultured with 0.25% trypsin and seeded into a Petri dish, 24 
or 96-well plate, for different experiments.
Cell viability assessment
Methylthiazoletetrazolium (MTT) assay was employed to 
assess cell viability (13). MTT assay was based on the abil-
ity of the viable cells to reduce soluble yellow MTT to blue 
formazan crystals. In this assay, optical density (OD) val-
ues represented the absorption of formazan dissolved by 
dimethyl sulfoxide at 570 nm. Cells (1 × 104 per well) were 
seeded in a 96-well plate containing 100 μL culture me-
dium. After 24 hours of incubation, the medium was re-
moved and refilled with new serum-free medium con-
taining different concentrations of paclitaxel for 24 hours, 
48 hours, and 72 hours incubation. At the indicated time 
points, MTT was added to reach a final concentration of 
0.5 mg/mL. After 4 hours of incubation at 37°C, the me-
dium was removed and the precipitate in each well was 
dissolved in dimethylsulfoxide. The plates were incubated 
for another 20 minutes in the dark. The OD values were 
measured at 570 nm using an ELISA reader (Multiskan MK3, 
Thermo Labsystems, Vantaa, Finland). Cell relative viability 
was calculated according to the following formula:
Cell relative viability (%) = ODexperiment/ODcontrol × 100% (OD-
blank was used as base point)
morphological observation
Morphological changes of Hep-2 cells in response to pacli-
taxel treatment were evaluated by staining cells with acri-
dine orange. Cells (5 × 104/per well) were seeded in 24-well 
dishes containing 1 mL culture medium. After 24 hours of 
incubation, the medium was removed and refilled with 
new serum-free medium containing paclitaxel (10 × 10−9 
mol/L) for 24 hours, 48 hours, and 72 hours incubation. The 
cells were washed twice by phosphate buffered solution, 
fixed by 95% alcohol for 10 minutes, and stained by 0.01% 
acridine orange for 5 minutes. The morphological changes 
were examined by fluorescence microscope. The cells with 
typical features of nuclear fragmentation and/or marked 
condensation of chromatin with reduced nuclear size were 
interpreted as apoptotic cells.
flow cytometry analysis
Cell apoptotic progression was assessed by flow cy-
tometry using Annexin V-FITC and propidium io-
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dide (PI). Cells (5 × 104/ml) were seeded in 6-well dishes 
and were treated with paclitaxel for 24 hours, 48 hours, 
and 72 hours. After treatment, cells were trypsinized and 
washed with phosphate-buffered saline. After washing, 
cells (1 × 107/mL) were resuspended in binding buffer (200 
μL) containing Annexin V-FITC (5μL, 20 μg/mL) and PI (10 
μL, 20 μg/mL) for at least 15 minutes at room temperature, 
and then added binding buffer (300 μL) before analysis 
with a System II, version 3.0 (Beckman Coulter Company, 
Miami, FL, USA)
rna isolation and reverse transcription-polymerase 
chain reaction (rt-PCr)
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, 
CA, USA) and was further purified with RNeasy purification 
kit (Qiagen, Chatsworth, CA, USA). The reverse transcrip-
tion reaction was performed using the ExScriptRT reagent 
kit (TaKaRa, Dalian, China) in a final volume of 20 μL con-
taining 1 μg total RNA, 4 μL 5 × ExScript buffer, 1μL deoxy-
nucleotide triphosphate mixture, 1 μL OligodT primer, 0.5 
μL ExScript RTase, 0.5 μL RNase inhibitor, and RNase-free 
water to a volume of 20 μL. The reverse-transcription reac-
tion was performed at 42°C for 15 minutes and terminated 
by heating at 95°C for 2 minutes. PCR was performed fol-
lowing the instruction of TaKaRa TaqTM under the follow-
ing conditions: pre-degeneration at 95°C for 3 minutes, de-
generation at 95°C for 60 seconds, renaturation at 58°C for 
45 seconds, and elongation at 72°C for 60 seconds, for a 
total of 25 cycles. All experiments were conducted 3 times. 





Protein extraction and Western blot analysis
The Hep-2 cells were harvested and lysed with a cold ra-
dioimmune precipitation buffer protein lysis buffer for 30 
minutes on ice. The lysates were transferred to Eppen-
dorf tubes and clarified by centrifugation at 12 000 × g for 
15 minutes at 4°C. The supernatant was kept at -80°C for 
future use. The Bradford method was used to determine 
the protein concentration of the supernatant. Samples 
(60 μg of total protein each) were boiled at 95°C for 5 
minutes and loaded onto sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (5% stacking gel and 
15% separating gel), followed by a separation at 80 V for 
about 2 hours and subsequent transfer to a polyvinylidene 
difluoride membrane. The membrane was blocked in 5% 
defatted milk for 1 hour at room temperature, incubated 
in the first antibodies (TWIST1:200, rabbit anti-human; ac-
tin, 1:2000, mouse anti-human), and diluted in 5% defat-
ted milk/Tris-buffered saline-Tween (TBS-T) overnight at 
4°C. After washing with TBS-T, the membrane was incu-
bated with a secondary antibody against mouse or rab-
bit IgG accordingly and the signals were visualized using 
electrochemiluminescence). The actin and TWIST bands 
were visualized at apparent molecular weights of 43 kDa 
and 28 kDa, respectively. Relative OD value ratio was cal-
culated with National Institutes of Health software Image J 
(http://rsbweb.nih.gov/ij/), by comparing it with actin from 
3 experiments.
Statistical analysis
Data were presented as mean ± standard deviation. One-
way analysis of variance and least significance difference 
was applied to analyze the data. P values lower than 0.05 
(two-tailed) were considered significant. Statistical calcula-
tions were performed using SPSS software package, ver-
sion 13.0 (SPSS Inc., Chicago, IL, USA).
reSuLtS
effects of paclitaxel on cell viability in Hep-2 cells
As evidenced by MTT assay, paclitaxel treatment resulted 
in the reduction of cell viability of Hep-2 cells in a concen-
tration- and time-dependent (Figure 1).
effects of paclitaxel on morphological changes in Hep-2 
cells
Morphological changes of Hep-2 cells were first examined 
by acridine orange cytochemistry staining at 24 hours, 48 
hours, or 72 hours after treatment with paclitaxel (10 × 10−9 
mol/L) (Figure 2). Cells without paclitaxel treatment showed 
polygonal shape and cells treated with paclitaxel became 
rounded and had cytoplasmic contraction and chromatin 
condensation. Apoptotic bodies, the main morphological 
characteristic of apoptosis were present.
flow cytometry analysis
Flow cytometric analysis (Figure 3 and Table 1) showed 
that the apoptotic rates at 24 hours, 48 hours, or 72 hours 
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tabLe 1. flow cytometric analysis of apoptotic cells of Hep-2 
cells induced by paclitaxel after staining with annexin V(an)-
fitC/propidium iodide (Pi)*
Percent of cells (%)
Quadrants a b C d
D1  9.85 ± 5.83 22.60 ± 5.30† 38.7 ± 7.90† 52.4 ± 14.27†
D2  4.16 ± 5.05  6.01 ± 5.14  4.57 ± 5.66  4.93 ± 5.18
D3 80.30 ± 9.50 67.53 ± 6.01 55.83 ± 5.81 40.3 ± 5.06
D4  4.83 ± 5.27  3.22 ± 5.00  3.07 ± 5.22  4.93 ± 5.79
*raw data for each group derived from the figure 3. Statistical analy-
sis was performed to assess the difference in apoptosis in quadrant 
d1 between the treated and control group. data were presented as 
mean ± standarad deviation. all experiments were conducted three 
times.
†Significant difference in apoptotic rate in group b, C, or d, each in 
comparison with group a (P = 0.002).
after the administration of paclitaxel (10 × 10−9 mol/L) were 
22.6 ± 5.3%, 38.7 ± 7.9%, and 52.4 ± 14.3%, respectively, 
while the control values were 9.9 ± 5.8% (P = 0.002).
Alteration in expression of tWiSt mRNA in Hep-2 cells
To study role of TWIST in response to paclitaxel treatment, 
TWIST expression at RNA level was first examined by semi-
quantitative RT-PCR. The expression of TWIST in Hep-2 was 
decreased at 24 hours, 48 hours, or 72 hours after treat-
ment with paclitaxel (Figure 4).
Alteration in expression of tWiSt protein in Hep-2 cells
The expression of TWIST protein was further examined by 
Western blotting (Figure 5). The data from Western blot-
ting experiment showed that the expression in the con-
trol group was 3.21 ± 0.05 optical density units, compared 
with 2.68 ± 0.06 at 24 hours, 1.69 ± 0.03 at 48 hours, and 
0.95 ± 0.03 at 72 hours in treated groups (P < 0.001). The al-
teration in protein paralleled the changes in mRNA levels.
Discussion
The present study demonstrated that paclitaxel decreased 
cell survival rates in a concentration- and time-dependent 
manner as evidenced by MTT assay, indicating that paclit-
axel can block cell growth of Hep-2 cells. Hep-2 cells treat-
ed with paclitaxel also showed cellular rounding, cytoplas-
mic contraction, chromatin condensation, and apoptotic 
body formation. These morphological changes are in ac-
cordance with typical characteristics of cells experiencing 
apoptosis (14). Moreover, the apoptotic rates of cells ex-
posed to paclitaxel were increased, further confirming the 
occurrence of apoptosis rather than necrosis. Our data are 
similar to a previous report, which showed that paclitaxel 
induced apoptosis in other solid tumor cell in in vitro stud-
ies (15).
Wang et al (16) reported that up-regulation of TWIST was 
responsible for development of acquired resistance to pa-
clitaxel in HNE1-T3, a nasopharyngeal carcinoma cell line. 
Subsequent studies also demonstrated that the TWIST-me-
diated paclitaxel resistance may be regulated through its 
Figure 1.
effects of paclitaxel on cell viability of Hep-2 cells. the survival rates 
of Hep-2 cells decreased in concentration- and time-dependent man-
ner. all experiments were performed in triplicate. data are expressed as 
means ± standard deviation percent of the control. Significant differenc-
es vs control: asterisk – P = 0.001, closed triangle – P = 0.002, open trian-
gle – P <0.001); open bars – 24 hours, closed bars – 48 hours, diagonally 
striped bars – 72 hours.
Figure 2.
morphological changes in Hep-2 cells treated with Paclitaxel 
(10 × 10−9mol/L) using acridine orange fluorescence microscopy ( × 200). 
(a) control; (b) 24 hours; (C) 48 hours; (d) 72 hours.
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positive involvement in the Akt pathway (17). Although pa-
clitaxel-induced cell death is thought to trigger apoptotic 
pathway in certain types of carcinoma, the exact mecha-
nisms responsible for paclitaxel-induced cell death in head 
and neck cancers are not well understood. To address this 
issue, we focused on investigating whether TWIST was a 
key determinant in paclitaxel-induced Hep-2 cell death. 
In this study, it was for the first time clearly demonstrated 
that the both mRNA and protein expression of TWIST 
decreased in the paclitaxel-induced apoptosis of 
Figure 3.
flow cytometric analysis of apoptotic cells of Hep-2 cells induced by paclitaxel after staining with annexin V(an)-fitC/propidium iodide (Pi). Histogram 
for an/Pi bivariate analysis. x-axis represents the density of Pi, y-axis represents the density of annexin V-fitC. d1, upper-left quadrant, contains an+/Pi-, 
early apoptotic cells; d2, upper-right quadrant, contains an+/Pi+, secondary necrotic cells; d3, lower-left quadrant, contains an-/Pi-, viable, non-apop-
totic cells; d4, lower-right quadrant, contains an-/Pi+, damaged viable cells. (a) control; (b) 24 hours; (C) 48 hours; (d) 72 hours.
Figure 4.
the alteration in expression of tWiSt mrna in Hep-2 cells treated with 
paclitaxel at different times, as assessed by reverse transcription-polymer-
ase chain reaction analysis.
Figure 5.
the alteration in expression of tWiSt protein in Hep-2 cells. (a) the al-
teration in expression levels of tWiSt protein in different times treated 
with Paclitaxel by Western blotting analysis. (b) the optical densities val-
ue of tWiSt protein in each lane using national institutes of Health soft-
ware image J system were demonstrated in different times treated with 
paclitaxel. each data point in the figure represents the mean ± standard 
deviation of 3 separate experiments. all experiments were conducted 
3 times. asterisk represents statistically significant difference vs control 
(P < 0.001).
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Hep-2 cells. This suggested that TWIST might be involved 
in paclitaxel-induced apoptosis of Hep-2 cells. It has been 
reported that high expression of TWIST can lead to in-
crease in chemoresistance to paclitaxel (18,19); converse-
ly, inactivation of TWIST in the nasopharyngeal carcinoma 
cells through small RNA interference led to increase in sen-
sitivity to paclitaxel (17). Our findings, together with these 
reports, reaffirm the positive role of TWIST in the develop-
ment and progression of human cancer. At present, two 
key apoptotic pathways are known, ie, the mitochondrial 
pathway and the death receptor pathway, both of which 
lead to activation of caspase cascades though a series of 
interactions. This poses the question whether TWIST is in-
volved in these two classical pathways, which remains to 
be answered in our future work.
In conclusion, the present study demonstrated that tran-
scription factor TWIST participated in paclitaxel-induced 
apoptosis of Hep-2 cells. The precise role of TWIST under-
lying the action of paclitaxel needs to be further explored. 
The intensive investigation of TWIST might not only con-
tribute to obtaining a new insight into the mechanism of 
chemoresistance, but offers a new target for the treatment 
of tumor.
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